<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43604">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991925</url>
  </required_header>
  <id_info>
    <org_study_id>UZL-INT-01</org_study_id>
    <nct_id>NCT01991925</nct_id>
  </id_info>
  <brief_title>Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis</brief_title>
  <official_title>Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hereditary haemochromatosis will be interviewed/questioned about their Quality
      of life and the delivered quality of care in the hospital.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>evaluation of quality of life</measure>
    <time_frame>after 3 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hereditary Haemochromatosis</condition>
  <arm_group>
    <arm_group_label>quality of life, quality of care</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviews, questionaires, RAND-modified delphi method round</intervention_name>
    <description>phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionaires and focusgroup interviews</description>
    <arm_group_label>quality of life, quality of care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Phase 1: RAND-modified Delphi Method: experts in the field of hereditary haemochromatosis
        Phase 2: Patients with hereditary haemochromatosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  phase 1: experts in the field of haemochromatosis (hepatologists, hematologists,
             endocrinologists, general practitioner, nurses, ...)

          -  phase 2: patients with hereditary haemochromatosis, treatment with phlebotomy since 3
             months, Dutch/English speaking

        Exclusion Criteria:

          -  patients with secundary iron overload

          -  phlebotomy treatment less than 3 months

          -  language: no Dutch or English
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annick Vanclooster, Nurse</last_name>
    <phone>0032-16-348472</phone>
    <email>annick.vanclooster@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annick Vanclooster, Nurse</last_name>
      <phone>0032-16-348472</phone>
      <email>annick.vanclooster@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Annick Vanclooster</investigator_full_name>
    <investigator_title>Nurse</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemochromatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
